Imatinib mesylate in desmoplastic small round cell tumors

Rita De Sanctis, Alexia Bertuzzi, Gianni Bisogno, Modesto Carli, Andrea Ferrari, Alessandro Comandone, Armando Santoro

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: To investigate the possible role of imatinib, an inhibitor of the tyrosine kinase activity of PDGF-R, in desmoplastic small round cell tumor (DSRCT). Patients & methods: From August 2005 to June 2009, DSRCT patients refractory to conventional treatment were enrolled. Patients received imatinib 400 mg daily. Primary end point of this open label, prospective, Phase II trial was objective response rate. Results: Of the 13 enrolled patients, eight were evaluable for response. Median age was 20 years (range: 9-32). Objective responses at 3 months were: stable disease in one patient and progressive disease in seven patients. Conclusion: Imatinib showed no efficacy in the treatment of DSRCT unresponsive to conventional therapy, despite molecular-based selection of patients.

Original languageEnglish
Pages (from-to)1233-1237
Number of pages5
JournalFuture Oncology
Volume13
Issue number14
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Desmoplastic Small Round Cell Tumor
Protein-Tyrosine Kinases
Patient Selection
Imatinib Mesylate
Therapeutics

Keywords

  • c-KIT
  • desmoplastic small round cell tumor
  • imatinib
  • PDGF-Rα
  • PDGF-Rβ

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Imatinib mesylate in desmoplastic small round cell tumors. / De Sanctis, Rita; Bertuzzi, Alexia; Bisogno, Gianni; Carli, Modesto; Ferrari, Andrea; Comandone, Alessandro; Santoro, Armando.

In: Future Oncology, Vol. 13, No. 14, 01.06.2017, p. 1233-1237.

Research output: Contribution to journalArticle

De Sanctis, Rita ; Bertuzzi, Alexia ; Bisogno, Gianni ; Carli, Modesto ; Ferrari, Andrea ; Comandone, Alessandro ; Santoro, Armando. / Imatinib mesylate in desmoplastic small round cell tumors. In: Future Oncology. 2017 ; Vol. 13, No. 14. pp. 1233-1237.
@article{b81852dadfad400699b1c1c425e08737,
title = "Imatinib mesylate in desmoplastic small round cell tumors",
abstract = "Aim: To investigate the possible role of imatinib, an inhibitor of the tyrosine kinase activity of PDGF-R, in desmoplastic small round cell tumor (DSRCT). Patients & methods: From August 2005 to June 2009, DSRCT patients refractory to conventional treatment were enrolled. Patients received imatinib 400 mg daily. Primary end point of this open label, prospective, Phase II trial was objective response rate. Results: Of the 13 enrolled patients, eight were evaluable for response. Median age was 20 years (range: 9-32). Objective responses at 3 months were: stable disease in one patient and progressive disease in seven patients. Conclusion: Imatinib showed no efficacy in the treatment of DSRCT unresponsive to conventional therapy, despite molecular-based selection of patients.",
keywords = "c-KIT, desmoplastic small round cell tumor, imatinib, PDGF-Rα, PDGF-Rβ",
author = "{De Sanctis}, Rita and Alexia Bertuzzi and Gianni Bisogno and Modesto Carli and Andrea Ferrari and Alessandro Comandone and Armando Santoro",
year = "2017",
month = "6",
day = "1",
doi = "10.2217/fon-2016-0305",
language = "English",
volume = "13",
pages = "1233--1237",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Imatinib mesylate in desmoplastic small round cell tumors

AU - De Sanctis, Rita

AU - Bertuzzi, Alexia

AU - Bisogno, Gianni

AU - Carli, Modesto

AU - Ferrari, Andrea

AU - Comandone, Alessandro

AU - Santoro, Armando

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Aim: To investigate the possible role of imatinib, an inhibitor of the tyrosine kinase activity of PDGF-R, in desmoplastic small round cell tumor (DSRCT). Patients & methods: From August 2005 to June 2009, DSRCT patients refractory to conventional treatment were enrolled. Patients received imatinib 400 mg daily. Primary end point of this open label, prospective, Phase II trial was objective response rate. Results: Of the 13 enrolled patients, eight were evaluable for response. Median age was 20 years (range: 9-32). Objective responses at 3 months were: stable disease in one patient and progressive disease in seven patients. Conclusion: Imatinib showed no efficacy in the treatment of DSRCT unresponsive to conventional therapy, despite molecular-based selection of patients.

AB - Aim: To investigate the possible role of imatinib, an inhibitor of the tyrosine kinase activity of PDGF-R, in desmoplastic small round cell tumor (DSRCT). Patients & methods: From August 2005 to June 2009, DSRCT patients refractory to conventional treatment were enrolled. Patients received imatinib 400 mg daily. Primary end point of this open label, prospective, Phase II trial was objective response rate. Results: Of the 13 enrolled patients, eight were evaluable for response. Median age was 20 years (range: 9-32). Objective responses at 3 months were: stable disease in one patient and progressive disease in seven patients. Conclusion: Imatinib showed no efficacy in the treatment of DSRCT unresponsive to conventional therapy, despite molecular-based selection of patients.

KW - c-KIT

KW - desmoplastic small round cell tumor

KW - imatinib

KW - PDGF-Rα

KW - PDGF-Rβ

UR - http://www.scopus.com/inward/record.url?scp=85021448247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021448247&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0305

DO - 10.2217/fon-2016-0305

M3 - Article

VL - 13

SP - 1233

EP - 1237

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -